Aurobindo Pharma clarifies volume movement linked to government import price policy

Regulatory & Legal View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.7%Reaction day

₹1198.90

prior close

₹1177.50

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-1.1%-0.6% vs market

Pharmaceuticals peers, median of 155sector-0.5%-1.2% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Midcap 150 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.1

15m

-0.1

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.7-1.1-0.6-0.5-1.2

Next day

+1.9+1.8+0.2+1.4+0.5

+1.2+2.4-1.2+1.6-0.5

-1.8+2.1-3.9+0.9-2.7

-0.3+2.0-2.4+0.4-0.8

+0.4+3.6-3.2+2.4-2.0

-4.7+4.1-8.8+2.5-7.2

15d

-4.2+1.8-6.0+0.5-4.7

+1.1-0.1+1.2-1.9+3.0

+11.4-7.8+19.3-6.5+17.9

+14.7+3.1+11.6+3.1+11.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma clarified to exchanges that the recent surge in share trading volume is purely market driven. The trigger is the Government's January 29, 2026 notification imposing Minimum Import Price (MIP) on Penicillin-G, 6-APA, and Amoxicillin Trihydrate imports. The company's wholly owned subsidiary Lyfius Pharma manufactures these products. Aurobindo confirmed all material information is already public and no undisclosed price-sensitive information exists.

Likely market impact

Positive context: import price curbs may help domestic makers including Lyfius Pharma. Stock already reacting to public news, no hidden catalysts.